BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Pfizer and Astellas Expand FDA Approval of PADCEV Plus Keytruda Across All Muscle-Invasive Bladder Cancer Patients

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...

July 13, 2026 | News

HanchorBio Partners with InxMed to Explore New Combination Strategies for Lead Cancer Therapy

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...

July 13, 2026 | News

J-Pharma Advances First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer

Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international...

July 08, 2026 | News

Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio

Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...

July 07, 2026 | News

Abbisko and AstraZeneca Partner to Advance Novel Oral IO-TKI Combination for EGFR-Mutant Lung Cancer

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, announced that it has entered into a strategic collaboration agreement with AstraZeneca (...

July 03, 2026 | News

METiS TechBio Signs US$1.62 Billion Licensing Deal for AI-Designed Cancer Therapy with Boulevard Bio

METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, announced it has entered into an exclusive global licensing agreement ...

July 02, 2026 | News

Colossal Foundation and University of Tasmania Partner to Fight Deadly Tasmanian Devil Cancer with Gene Editing and Vaccines

The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer...

July 01, 2026 | News

Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

July 01, 2026 | News

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 for EGFR-Mutant Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...

June 29, 2026 | News

Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...

June 25, 2026 | News

China Approves World's First CAR-T Therapy for Solid Tumours

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...

June 24, 2026 | News

Sonire Lands Major Japanese Government Backing to Advance Next-Generation Cancer Ultrasound Therapy

Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therapeut...

June 19, 2026 | News

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Stay Connected